Building consistency in
HER2 IHC assessment
in breast cancer

Around 50% of breast cancers express low levels of HER2 in the absence of gene amplification, and are described as IHC 1+ or IHC 2+ with negative ISH. This proposed algorithm¹ represents a pragmatic approach to HER2 IHC interpretation, as we begin to distinguish between HER2 negative and HER2 low expression.

Put your HER2 IHC knowledge to the test by assessing challenging clinical breast cancer cases featuring a carousel of whole slide images. Select the HER2 IHC score you would assign to each case and check whether your scores align with others in the pathology community.